N-dichloromethylene pyrrolidinium chloride | 73511-34-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: N-dichloromethylene pyrrolidinium chloride
• 英文别名: N-pyrrolidinophosgeniminium chloride；1-(Dichloromethylidene)pyrrolidin-1-ium;chloride
• CAS: 73511-34-9
• 化学式: C₅H₈Cl₂N*Cl
• 分子量: 188.484
• InChiKey: RMFGNQHPRDKZBA-UHFFFAOYSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  -1.37
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  3
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  N-dichloromethylene pyrrolidinium chloride 以86.5%的产率得到4-chlorobutylisocyanide dichloride
  参考文献：
  名称：

  Guillot, N.; Marin, B.; Janousek, Z., Synthetic Communications, 1989, vol. 19, # 16, p. 2825 - 2832

  摘要：

  DOI：

文献信息

• [EN] IMINOTETRAHYDROPYRIMIDINONE DERIVATIVES AS PLASMEPSIN V INHIBITORS<br/>[FR] DÉRIVÉS D'IMINOTÉTRAHYDROPYRIMIDINONE UTILISÉS COMME INHIBITEURS DE PLASMEPSINE V
  申请人：UCB BIOPHARMA SPRL

  公开号：WO2017089453A1

  公开（公告）日：2017-06-01

  A series of 2-imino-6-methyltetrahydropyrimidin-4(lH)-one derivatives, substituted in the 6-position by a phenyl moiety which in turn is meta-substituted by an optionally substituted unsaturated fused bicyclic ring system containing at least one nitrogen atom, being selective inhibitors of plasmepsin V activity, are beneficial as pharmaceutical agents, especially in the treatment of malaria.

  一系列在6-位置被苯基取代的2-亚氨基-6-甲基四氢嘧啶-4(1H)-酮衍生物，该苯基再通过一个可选取代的不饱和融合双环环系统进行间位取代，该环系统含有至少一个氮原子，作为血液型质体蛋白酶V活性的选择性抑制剂，对于药物制剂特别有益，尤其在治疗疟疾方面。
• [EN] IMINOTHIADIAZINANE DIOXIDE DERIVATIVES AS PLASMEPSIN V INHIBITORS<br/>[FR] DÉRIVÉS DE DIOXYDE D'IMINOTHIADIAZINANE UTILISÉS COMME INHIBITEURS DE LA PLASMEPSINE V
  申请人：UCB BIOPHARMA SPRL

  公开号：WO2017144517A1

  公开（公告）日：2017-08-31

  A series of 3-imino-5-methyl-1,2,4-thiadiazinane 1,1-dioxide derivatives of formula (I), substituted in the 5-position by a phenyl moiety which in turn is meta-substituted by an optionally substituted fused bicyclic heteroaromatic ring system containing at least one nitrogen atom, being selective inhibitors of plasmepsin V activity, are beneficial as pharmaceutical agents, especially in the treatment of malaria.

  一系列的3-亚胺基-5-甲基-1,2,4-噻二唑烷-1,1-二氧化物衍生物，化学式为(I)，在5位被苯基取代，而该苯基又被一个可选择取代的融合双环杂芳环系统取代，该系统含有至少一个氮原子，这些化合物对疟原虫V蛋白酶活性具有选择性抑制作用，在药物方面具有益处，尤其在治疗疟疾方面。
• A Mild and regiospecific synthesis of 3-amino substituted triazolo-[4,3-c]-pyrimidines by cyclisation of 4-hydrazinopyrimidines with iminium chlorides and with N-aryl phosgenimines
  作者：N. Guillot、H.G. Viehe、B. Tinant、J.P. Declercq

  DOI：10.1016/s0040-4020(01)90525-3

  日期：1990.1

  Phosgeniminium chloride (PI) 1a permits the regiospecific synthesis of 3-dimethylaminotriazolo-[4,3-ch-pyrimidine 8a from the corresponding 4-hydrazinopyrimidine 5 without Dimroth type isomerisation into its [1,5-c isomer. This synthesis has been extended to the cyclic phosgeniminium salts lb–e and to the N-aryl phosgenimines (aryl isocyanide dichlorides) 18a,b. The triazolopyrimidine structure was

  氯化亚磷鎓（PI）1a允许从相应的4-肼基嘧啶5进行区域特异性合成3-二甲基氨基三唑-[4,3- ch-嘧啶8a]，而无需Dimroth型异构化为其[1,5-c]异构体。该合成方法已扩展到环状光气亚胺盐lb-e和N-芳基光气亚胺（芳基异氰化物二氯化物）18a，b。通过衍生物8d的X射线衍射分析确认了三唑并嘧啶的结构。当维尔斯迈尔盐10时，四甲基脲二氯化物11或二甲基（2,2,2-三氟-1,1-二氯乙基）胺12被用作亲电试剂，4- methylenehydraiinopyrimidines 13，14和15分别进行分离。热分解13产生具有相同的区域专一3-未取代的三唑并〔4,3-C-嘧啶16。该化合物可以在一个单独的步骤中重新排列为17。hydrazidopyrimidine的氯化20在回流的POCl 3导致了异构化的三唑并- [1,5-CH-嘧啶22，通过X射线衍射和作为确定13 C-NMR分析。
• Iminothiadiazinane dioxide derivatives as plasmepsin V inhibitors
  申请人：UCB Biopharma SPRL

  公开号：US10464932B2

  公开（公告）日：2019-11-05

  A series of 3-imino-5-methyl-1,2,4-thiadiazinane 1,1-dioxide derivatives of formula (I), substituted in the 5-position by a phenyl moiety NH which in turn is meta-substituted by an optionally substituted fused bicyclic heteroaromatic ring system containing at least one nitrogen atom, being selective inhibitors of plasmepsin V activity, are beneficial as pharmaceutical agents, especially in the treatment of malaria.

  一系列式（I）的 3-亚氨基-5-甲基-1,2,4-噻二嗪烷 1,1-二氧化物衍生物，在 5 位被苯基 NH 取代，而苯基 NH 又被含有至少一个氮原子的任选取代的融合双环杂芳香族环系统元取代，是胰凝乳蛋白酶 V 活性的选择性抑制剂，可用作药物，特别是治疗疟疾。
• Iminotetrahydropyrimidinone derivatives as plasmepsin V inhibitors
  申请人：UCB Biopharma SPRL

  公开号：US11136310B2

  公开（公告）日：2021-10-05

  A series of 2-imino-6-methyltetrahydropyrimidin-4(1H)-one derivatives, substituted in the 6-position by a phenyl moiety which in turn is meta-substituted by an optionally substituted unsaturated fused bicyclic ring system containing at least one nitrogen atom, being selective inhibitors of plasmepsin V activity, are beneficial as pharmaceutical agents, especially in the treatment of malaria.

  一系列 2-亚氨基-6-甲基四氢嘧啶-4(1H)-酮衍生物，在 6 位被苯基取代，而苯基又被含有至少一个氮原子的任选取代的不饱和融合双环体系元取代，是胰蛋白酶 V 活性的选择性抑制剂，可用作药物，特别是治疗疟疾。